Q3 2025 Fresenius Medical Care AG Earnings Call Transcript
Key Points
- Fresenius Medical Care AG (FMS) reported strong organic revenue growth of 10% in Q3 2025, with positive contributions from all three operating segments.
- Operating income growth increased for the third consecutive quarter, accelerating to 28%, and the operating income margin expanded from 9.9% to 11.7%.
- The FME25+ program generated EUR47 million in sustainable savings in Q3, bringing the total savings for 2025 to EUR174 million.
- The company announced an initial share buyback of EUR1 billion, with EUR188 million already invested by October 31, 2025.
- Fresenius Medical Care AG (FMS) is on track to achieve its full-year 2025 outlook and has reiterated its guidance.
- The US government shutdown and uncertainties in healthcare policy decisions pose challenges for planning and operations.
- Delays by CMS in providing reporting data for the CKCC program are causing earnings fluctuations in the value-based care segment.
- The company faces higher labor costs, including elevated medical benefit costs, which are impacting profitability.
- Foreign exchange rates developed unfavorably, with a negative EUR24 million translational impact on operating income.
- The company is experiencing low same-market treatment growth in the US, which remains a challenge for future growth.
(technical difficulty)
(Operator Instructions)
At this time, it's my pleasure to hand over to Dr. Dominik Heger. Please go ahead, sir.
Thank you, Sandra. Welcome, everyone, to our earnings call for the third quarter 2025. As always, I start out the call by mentioning our cautionary language that is in our Safe Harbor statement as well as in our presentation and in all the materials that we have distributed earlier today. For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings.
We will have roughly 1 hour for the call. In order to give everyone the chance to ask questions, we would limit the number of questions to two. Thank you for making this work. As always, let me now welcome Helen Giza, CEO and Chair of the Management Board; and Martin Fischer, our Chief Financial Officer.
Helen, the floor is yours.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
